Breast Cancer Connect
  • Saved

6mo
Case Report: Comparison different response after neoadjuvant chemotherapy of the breast with cell-in-cell-report of two cases - PubMed

Case Report: Comparison different response after neoadjuvant chemotherapy of the breast with cell-in-cell-report of two cases - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41641261/

Neoadjuvant chemotherapy (NACT) is commonly applied in human epidermal growth factor receptor 2 (HER2)-positive breast cancer to reduce tumor size and increase the likelihood of breast-conserving surgery. However, predictive markers...

Two HER2-positive breast cancer cases showed contrasting responses to neoadjuvant chemotherapy; changes in cell-in-cell structures correlated with treatment response, suggesting CIC dynamics may serve as potential predictive markers.

  • Saved

6mo
Enhancing the Water Solubility and Efficacy of Anticancer Drugs Using Hydroxypropyl-β-Cyclodextrin - PubMed

Enhancing the Water Solubility and Efficacy of Anticancer Drugs Using Hydroxypropyl-β-Cyclodextrin - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41596562/

Cyclodextrins (CyDs) are cyclic oligosaccharides that form inclusion complexes that allow organic compounds and other substances to be incorporated into their cavities. Hydroxypropyl-β-cyclodextrin (HP-β-CyD) is frequently used to improve the...

Review highlights hydroxypropyl-β-cyclodextrin enhancing solubility, delivery, and efficacy of anticancer drugs, with emerging roles as an active agent via targeted delivery and autophagy-mediated mechanisms.

  • Saved

6mo

Pembrolizumab-Induced Colitis With Concurrent Capecitabine in Triple-Negative Breast Carcinoma: A Case Report - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41523718/

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their use is associated with immune-related adverse events (irAEs). Colitis is a significant irAE, particularly with programmed cell death protein 1...

Case report describes pembrolizumab-induced colitis during concurrent capecitabine in triple-negative breast cancer, highlighting diagnostic challenges, importance of histologic confirmation, and need for early recognition and management of immune-related colitis.

  • Saved

7mo
Genetic Testing for All Breast Cancer Patients: The GET FACTS Randomized Clinical Trial - PubMed

Genetic Testing for All Breast Cancer Patients: The GET FACTS Randomized Clinical Trial - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41525075/

ClinicalTrials.gov Identifier: NCT04245176.

This randomized trial showed personalized genetic risk counseling improved contralateral breast cancer risk understanding but did not change contralateral prophylactic mastectomy decisions, supporting informed discussions without influencing surgical choice.

  • Saved

7mo
SABCS 2025: Practice-Changing Trials and Evolving Standards in Breast Cancer Care

In this SABCS 2025 conference video, Dr. Virginia Kaklamani, Professor of Medicine at UT Health San Antonio and Co-Director of SABCS, discusses key advances shaping contemporary breast cancer care. Highlights include emerging applications of artificial intelligence in breast cancer management, findings from the HER2-CLYMO5 trial supporting chemotherapy de-escalation with tucatinib, and promising phase 3 data evaluating the oral selective estrogen receptor degrader giredestrant.

Dr. Isabel Bedrosian, Professor of Breast Surgical Oncology at MD Anderson Cancer Center, reviews results from the Alliance A11104 trial, which demonstrated that routine preoperative breast MRI did not improve locoregional control or survival in patients with early-stage breast cancer. These findings reinforce evidence-based surgical decision-making and support a more selective approach to preoperative imaging.

Share your thoughts